48 results about "Cotinine" patented technology

The invention is a chewing tobacco substitute made from natural leaves and additives which simulate the taste and consistency of chewing tobacco to which a nicotine compound is added. The invention allows those addicted to chewing tobacco to chew and receive nicotine without incurring the other harmful side effects of tobacco. In one embodiment of the invention the product is provided with varying levels of nicotine.

The invention discloses a synchronous analysis method for trace nicotine in blood-brain samples of an animal and main metabolites thereof. The synchronous analysis method is characterized by comprising the following steps of: utilizing a microdialysis system to synchronously collect blood dialysate and brain tissue dialysate samples of an animal in lined pipes of different chromatographic sampling bottles, respectively adding NIC-d3 and COT-d3 to be mixed with internal labeled solution, and after mixing uniformly, directly analyzing and detecting the content of the nicotine and cotinine in a microdialysis sample by using UPLC-MS / MS. The synchronous analysis method disclosed by the invention has the advantages that the pretreatment steps of protein precipitation and purification for the samples are not needed, the synchronous and accurate analysis of nicotine and metabolites in an animal body is realized; and compared with the prior art, the synchronous analysis method has the characteristics of simple operation, high sensitivity and reliable result and the like, and a new method for researching the metabolism of the nicotine in the animal body is provided.

The present application discloses monoclonal antibody against cotinine and nicotine.

The invention provides a burley tobacco nicotine extract product and an extraction technology for the same. The burley tobacco nicotine extract product is composed of the following components according to weight by percentage: 94 to 97% of nicotine, 0.4 to 0.6% of cotinine, 0.2 to 0.3% of N-methy pridine carboxamide, 0.1 to 0.2% of benzofuran, 0.1 to 0.2% of indol, 0.1 to 0.2% of 5.5-dimethyle pyrazoline, 0.05 to 0.15% of acetyl pridine, 0.05 to 0.1% of megastigmatrienone, 0.02 to 0.05% of hydroxide radical damascenone, 0.02 to 0.05% of palmitic acid and 0.01 to 0.04% of demethylation nicotine. The burley tobacco nicotine extract product has nigh nicotine content and has special flavor when prepared for electronic tobacco juice; electronic cigarette satisfaction can be enhanced; and the electronic cigarette can be closer to cigarette taste.

The invention provides a new nicotine-degrading bacteria-pseudomonas ZUTSKD and its application. The ZUTSKD (Pseudomonas sp.ZUTSKD) is stored in China Center for Type Culture Collection, the storing date was June 18th, 2007, the preservation no. is CCTCC NO:M 207083. The bacteria can degrade nicotine and generate such intermediate as 2, 3'-Bipyridine, cotinine, 3-(3, 4-dihydro-2H-pyrrol-5-y1)-Pyridine and 3-Pyridinecarboxylic acid, the max. nicotine concentration withstandable is 5.5 g / L. The invention can reduce the nicotine in waste cigarette residues, and is of certain application prospect in the industry.

The invention provides a flue-cured tobacco nicotine extract product and an extraction technology. The flue-cured tobacco nicotine extract product comprises the following components according to weight by percentage: 92 to 96% of nicotine, 0.5 to 1% of cotinine, 0.2 to 0.8% of 2,3-dhydro-3,5-dyhydroxy,6-methyl-4H-prone, 0.2 to 0.5% of hydroxymethylfurfural, 0.1 to 0.4% of 3-hydroxy-Beta-damascenone, 0.1 to 0.3% of megastigmatrienone, 0.1 to 0.3% of methyl heptenone, 0.1 to 0.2% of palmitic acid, and 0.05 to 0.1% of demethylation. The flue-cured tobacco nicotine extract product has high nicotine content, when prepared into electronic tobacco juice, has special flavor; and satisfaction of the electronic cigarette can be met, so the electronic cigarette can be closer to cigarette flavors.

The present invention relates to a multi portion intra-oral dosage form comprising at least one pharmaceutically active agent or health promoting agent wherein at least one portion comprises a component for creating a noticeable organoleptic sensation. Of certain interest is use of sensory markers / signals as conceptual aids for a subject using the dosage form whereby the organoleptic sensation / s is / are such that it / they facilitate / s for the subject to identify a portion and differentiate between different portions thereof. Also contemplated are a dosage form, a method and a system for delivering active agents, such as nicotine and / or metabolites thereof, such as cotinine, nicotine N'-oxide, nornicotine, (S)-nicotine-N--glucuronide and mixtures, isomers, salts and complexes thereof as well as use and production of said dosage forms.

The invention discloses an application of melatonin in preparation of a medicine for improving oocyte quality. According to the invention, melatonin is directly added into an oocyte in-vitro maturation culture solution, which proves that the melatonin can relieve the reduction of the quality of the cotinine-induced oocytes and is shown as reduction of the ROS level in the oocytes, reduction of aneuploidy formation, promotion of uniform distribution of actin, improvement of the form of spindles and improvement of mitochondrial functions, and then the later fertilization rate of the oocytes is remarkably increased. The invention provides a method for improving the influence of the main metabolite cotinine of nicotine in the blood of a smoker on the quality of female oocytes, and provides aneffective method for improving the reproductive capacity of smoking women.

The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

The invention discloses a method for evaluating the influences of smoking on the quality of oocytes. Specifically, oocytes are cultured to be mature in culture solutions containing different concentrations of cotinine. Finally, the influences of smoking on the quality of oocytes are evaluated by detecting some indicators, such as the maturation rate of oocytes, chromosomal aneuploidy, actin distribution, mitochondrial membrane potential, intracellular reactive oxygen species level, spindle morphology, chromosome arrangement of mature oocytes, sperm binding number after in-vitro fertilization,pronucleus formation rate after parthenogenetic activation and the like. Through a large number of objective tests, the influences of smoking on the quality of oocytes are evaluated, thus providing areference of theoretical data for the maintenance of reproductive capacity of female smokers.

The invention discloses a high-sensitivity and high-accuracy method for simultaneously determining NNAL and cotinine in urine. The method comprises the following steps: 1) preparing a single standardstock solution containing the NNAL, the cotinine, isotope-labeled NNAL and isotope-labeled cotinine; 2) preparing mixed standard sample working solutions having a series of concentrations and containing the NNAL and the cotinine, and making a standard curve; 3) taking a to-be-determined urine sample, adding a phosphate buffer solution containing an isotope-labeled internal standard, and adding 15-25 [mu]L of beta-glucuronidase for enzymolysis; and 4) taking out the sample solution subjected to the enzymolysis, naturally cooling the sample solution into the room temperature, performing solid-phase extraction, performing instrument analysis, and performing calculation according to the standard curve made in the step 2) to obtain the content of the NNAL and the cotinine. The method effectively solves the problems of complex pretreatment and long consumed time of an existing method for simultaneously testing the NNAL and the cotinine in the urine; and meanwhile, the matrix effect in the urine is greatly reduced, so that the detection sensitivity and accuracy are improved.

The invention discloses a population size survey method based on sewage concentration monitoring. The method specifically comprises the following steps of S1, determining a region where a pre-estimated popularization size is located, selecting a sewage treatment plant of the region, and collecting water inflow samples of the sewage treatment plant for pretreatment of the samples; S2, selecting a human metabolite of ammonia nitrogen and a tobacco metabolite of cotinine as biomarkers; S3 , measuring the concentration of ammonia nitrogen in measurement sewage by use of a national standard method,wherein the national standard method specifies that the concentration of ammonia nitrogen in measurement sewage is measured by use of a Nessler's Reagent spectrophotometric method; S4, measuring theconcentration of cotinine by use of a liquid chromatography-mass spectrometer or a gas chromatograph-mass spectrometer; and S5, calculating output per capita of the two biomarkers, and calculating bya biomarker method to obtain the popularization size of the region where the sewage treatment plant is located.

The subject invention concerns materials and methods for treating and / or preventing diseases associated with accumulation of Aβ peptide in neural tissue. The subject invention also concerns materials and methods for treating and / or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and / or treat Alzheimer's disease and Parkinson's disease. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant. The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer's disease and Parkinson's disease, using the chemical cotinine.

A composition suitable for use in nicotine replacement therapy products includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and / or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1'-N-oxide, nicotyrine, nornicotyrine, 2',3-bipyridyl, cotinine, anabasine, and / or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and / or carriers. The nicotine replacement therapy products may include any number of such products, including transdermal nicotine delivery patches, nicotine gums, synthetic chewing tobacco, synthetic snuff, and synthetic strips (e.g., dissolvable synthetic tobacco). Additionally, a method of treating nicotine addiction includes administering a nicotine replacement composition, e.g., via a nicotine replacement therapy product, to a user.

A composition suitable for use in a vaping device includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and / or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1'- N-oxide, nicotyrine, nornicotyrine, 2',3-bipyridyl, cotinine, anabasine, and / or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and / or solvents.

The present invention relates to a method of a) treating any of depression induced by chronic stress; depression in a subject afflicted with PTSD; anxiety induced by chronic stress; anxiety in a subject afflicted with PTSD; cognitive impairment induced by chronic stress; altered morphology and / or reduced number of GFAP+ cells in hippocampus and / or frontal cortex induced by chronic stress; working memory impairment in a subject afflicted with PTSD; b) inhibiting or reversing loss of GFAP+ cells in hippocampus and / or frontal cortex induced by chronic stress; c) decreasing consolidation of contextual fear memory in a subject afflicted with PTSD; d) enhancing extinction of fear memory in a subject afflicted with PTSD; or e) increasing calcineurin A expression in a subject afflicted with PTSD using a combination of cotinine and an antioxidant.

Disclosed is a chewing gum composition capable of eliminating nicotine component from the body of a person chewing the chewing gum. Such a chewing gum composition functions to convert the nicotine produced in a human body after smoking to cotinine and to discharge the cotinine into urine. Accordingly, by chewing the chewing gum of the present invention, not only nicotine can be eliminated from the body, but also the incidence of cancer due to nicotine can be largely reduced.

There is disclosed herein a device for determining the smoking status of a subject, wherein said device comprises a plurality of different specific binding molecules deposited to a solid phase to detect specifically the presence of two or three tobacco smoke exposure biomarkers in a biological sample, said biomarkers consisting of: (i) cotinine and total 4-(methylnitrosamino)-1-(3-, pyridyl)-1-butanol (NNAL); (ii) cotinine and N-acetyl-S-[2-carboxyethyl]-L-cysteine (CEMA); or (iii) cotinine and NNAL and CEMA.

Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.

The invention belongs to the field of cigarette products and discloses a cigarette with a mint flavor and a preparation method thereof. The cigarette with a mint flavor is made up of following ingredients such as paraffin, vaseline, propolis, nicotine, cotinine, neodiphene, furfural, violet alcohol, mezotone, geranyl acetone, catechol, dalcate, geranene, preservatives, sodium glycocholate, 5-hydroxymethyl furfural, ionone, purple yellow, mint flavor, the amount of pH regulators and the rest of stearic acid. The pH of the cigarette with a mint flavor ranges from 5.0 to 5.5. The cigarette with a mint flavor is used as a substitute for a conventional citrate and has the flavor, vigor and taste similar to the conventional one. The cigarette is convenient to carry and helps avoid fire disasters without combustion. People are not affected by smoke. Second-hand smoke is avoided. The cigratte has a broad application scope.

A method of inhibiting or treating chemotherapy-induced cognitive dysfunction comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced cognitive dysfunction.

The invention discloses an ovulation detection test strip. The ovulation detection test strip comprises a PVC bottom plate, a sample pad, a gold label pad, a nitrocellulose film and a water absorption pad, wherein the nitrocellulose film is provided with a detection line T1, a detection line T2 and a quality control line, the detection line T1 is coated with a mouse anti-human beta LH monoclonal antibody 1A4, the detection line T2 is coated with a cotinine antigen, and the quality control line is coated with a goat anti-chicken IgY polyclonal antibody; and a colloidal gold mouse anti-human beta LH monoclonal antibody 6B8 conjugate, a colloidal gold chicken IgY antibody conjugate and a colloidal gold cotinine monoclonal antibody conjugate are cured on the gold label pad. The test strip is high in detection sensitivity and good in specificity, abnormal interpretation results caused by crossing of LH with follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH) can be avoided, detection results are more accurate, and monitoring of the smoking metabolite cotinine in urine is combined. The invention further discloses an ovulation detection method, the steps are simple, and the test result is accurate.

The invention provides a method for analyzing nicotine and cotinine in urine, which includes the following steps: 1) Take a standard solution of nicotine and cotinine containing an internal standard, inject it into an enrichment device and carry out the process under auxiliary gas purging Adsorption enrichment, after thermal desorption under carrier gas purging, a standard sample containing an internal standard is obtained; 2) Take a urine sample, and use the same steps as step 1) to obtain a sample to be tested; 3) Separately The standard sample and the test sample containing the internal standard substance enter the GC-MS under the purging of the carrier gas for detection, compare the retention time according to the obtained mass spectrum for qualitative determination, determine the nicotine and cotinine components in the test sample, and The content of nicotine and cotinine in the sample to be tested is calculated by internal standard method. The method for analyzing nicotine and cotinine in urine provided by the invention is convenient, efficient, fast, high in sensitivity and good in repeatability, and can fully meet the analysis requirements of nicotine and cotinine in urine.

The present invention relates to a natural killer cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent comprising same. The natural killer cell expressing a chimeric antigen receptor specifically binding to cotinine, according to the present invention, can effectively move to tumor tissue, regardless of the kind of cancer,depending on the binding substance bound to cotinine. Therefore, the natural killer cell according to the present invention can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.

The invention discloses a method for simultaneously measuring the content of nicotine, 3-(pyrrolidine-2-yl) pyridine, (-)-cotinine and testosterone in serum. The method has the advantages of high simplicity, great rapidity, high detection sensitivity, strong pertinency and wide application range. It is verified that the method has a relatively great recycling property, good linear relation and relatively low quantitation limit for the measurement of the four target objects, can simultaneously detect a plurality of kinds of target objects at one time, and is rapid and efficient. The pretreatment method, liquid phase method and some liquid-mass methods of the method of the invention are also applicable to the analysis of other object objects similar to the above four components in serum, andtherefore, the method of the invention has high applicability.

A system for determining a level of cotinine in a sample includes a test strip system configured to receive a sample, the test strip system including a first lateral flow test strip and a second lateral flow test strip, the first and second lateral flow test strips each having an overlapping but non-identical range for cotinine. The system further includes a meter configured to receive the test strip, wherein the meter is configured to read the test strip and detect a level of cotinine.

The present invention relates to an antibody-drug composite using a bispecific antibody and a use thereof. According to the antibody-drug composite of the present invention, a composite of an antibodyand a drug can be easily formed by a binding of a conjugate of a bivalent cotinine-peptide and a drug and an anti-cotinine single chain variable fragment without the need of a multi-step synthesis procedure In addition, the antibody-drug composite of the present invention can effectively deliver the drug to a target to which the antibody specifically binds, and can improve the therapeutic effectby increasing the half-life of the drug in the body.